The pro-immune action of IFN gamma is well-known (41); in CML, interferon has a long history of successes, and it seems to be able to delete ABL1 mutations when added to TKIs, hence making patients sensitive again to treatment (58). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.